| Wed 10 Aug 2022, 7:06 | | MEDICLINIC INTERNATIONAL PLC - TR-1: Standard form for notification of major holdings |
|
TR-1: Standard form for notification of major holdings
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
(‘Mediclinic’, the ‘Company’, or the ‘Group’)
10 August 2022
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00B8HX8Z88
Issuer Name
MEDICLINIC INTERNATIONAL PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights; An acquisition or disposal of financial instruments
3. Details of person subject to the notification obligation
Name
JPMorgan Chase & Co.
City of registered office (if applicable)
Country of registered office (if applicable)
US
4. Details of the shareholder
Name City of registered office Country of registered office
J.P. Morgan Securities
5. Date on which the threshold was crossed or reached
05-Aug-2022
6. Date on which Issuer notified
09-Aug-2022
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting Total of both Total number of
rights attached rights through in % (8.A + voting rights
to shares (total financial 8.B) held in issuer
of 8.A) instruments
(total of 8.B 1 +
8.B 2)
Resulting 4.232665 4.881712 9.114377 67195773
situation on the
date on which
threshold was
crossed or
reached
Position of 1.308596 7.723660 9.032256
previous
notification (if
applicable)
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of Number of direct Number of indirect % of direct % of indirect
shares ISIN voting rights voting rights voting rights voting rights
code(if possible) (DTR5.1) (DTR5.2.1) (DTR5.1) (DTR5.2.1)
GB00B8HX8Z88 31205499 4.232665
Sub Total 8.A
31205499 4.232665%
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial Expiration Exercise/conversion Number of voting rights that % of
instrument date period may be acquired if the voting
instrument is rights
exercised/converted
Sub Total 8.B1
8B2. Financial Instruments with similar economic effect
according to (DTR5.3.1R.(1) (b))
Type of Expiration date Exercise/conversion Physical or Number of % of voting
financial period cash voting rights rights
instrument settlement
Cash- 23/11/2022 23/11/2022 Cash 28558635 3.873700
settled
Equity
Swap
Cash- 01/02/2023 01/02/2023 Cash 16152 0.002190
settled
Equity
Swap
Cash- 22/02/2023 22/02/2023 Cash 20437 0.002771
settled
Equity
Swap
Cash- 17/03/2023 17/03/2023 Cash 28523 0.003868
settled
Equity
Swap
Cash- 02/06/2023 02/06/2023 Cash 143409 0.019452
settled
Equity
Swap
Cash- 04/07/2023 04/07/2023 Cash 7109658 0.964353
settled
Equity
Swap
Cash- 12/07/2023 12/07/2023 Cash 13127 0.001779
settled
Equity
Swap
Cash- 09/08/2023 09/08/2023 Cash 759 0.000102
settled
Equity
Swap
Cash- 16/08/2023 16/08/2023 Cash 2400 0.000324
settled
Equity
Swap
Cash- 21/08/2023 21/08/2023 Cash 526 0.000070
settled
Equity
Swap
Cash- 22/08/2023 22/08/2023 Cash 598 0.000081
settled
Equity
Swap
Cash- 06/07/2027 06/07/2027 Cash 309 0.000041
settled
Equity
Swap
Cash- 03/08/2027 03/08/2027 Cash 289 0.000038
settled
Equity
Swap
Cash- 09/07/2029 09/07/2029 Cash 65281 0.008853
settled
Equity
Swap
Cash- 12/02/2024 12/02/2024 Cash 13023 0.001766
settled
Equity
Swap
Cash- 06/09/2023 06/09/2023 Cash 13795 0.001870
settled
Equity
Swap
Cash- 07/09/2023 07/09/2023 Cash 3353 0.000454
settled
Equity
Swap
Sub Total 8.B2
35990274 4.881712%
9. Information in relation to the person subject to the
notification obligation
2. Full chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held starting with the
ultimate controlling natural person or legal entities (please add
additional rows as necessary)
Ultimate Name of controlled % of voting % of voting rights Total of both if it
controlling person undertaking rights if it through financial equals or is higher
equals or is instruments if it than the notifiable
higher than equals or is higher threshold
the notifiable than the notifiable
threshold threshold
JPMorgan J.P. Morgan 4.881712 7.180133%
Chase & Co. Securities plc
JPMorgan JPMorgan
Chase & Co. Chase Bank,
National
Association
JPMorgan J.P. Morgan
Chase & Co. Equities
South Africa
Proprietary
Limited
JPMorgan J.P. Morgan
Chase & Co. SE
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
Chain of controlled undertakings:
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan Capital Holdings Limited (100%)
J.P. Morgan Securities plc (100%)
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan Capital Holdings Limited (100%)
J.P. Morgan Equities South Africa Proprietary Limited (100%)
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan SE (100%)
12. Date of Completion
09-Aug-2022
13. Place Of Completion
London
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in
South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and
Namibia) and the Middle East.
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across
the continuum of care in such a way that the Group will be regarded as the most respected
and trusted provider of healthcare services by patients, medical practitioners, funders and
regulators of healthcare in each of its markets.
At 30 June 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental
health facilities, 20 day case clinics and 23 outpatient clinics. The Swiss operations
included 17 hospitals and four day case clinics with around 1 900 inpatient beds; Southern
Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals,
two mental health facilities and 14 day case clinics (four of which operated by Intercare)
across South Africa, and around 8 650 inpatient beds; and the Middle East operated seven
hospitals, two day case clinics and 23 outpatient clinics with around 1 000 inpatient beds in
the UAE. In addition, under management contract the Middle East will open a 200-bed
hospital in the Kingdom of Saudi Arabia in 2023.
The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United
Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock
Exchange in Namibia.
Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a leading private
healthcare group based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor Relations
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS
Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 10-08-2022 07:06:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
